Physician profile
James Robert Carroll
NPI 1841272432
$3,851.44
in general payments reported to CMS, 2019-2025
20 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $151 · 2021: $356 · 2022: $291 · 2023: $1,051 · 2024: $715 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $608.06 | 2019-2025 | |
| Pfizer INC. | $454.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.90 | 2022-2025 | Jardiance |
| Amgen INC. | $296.69 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $261.53 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $255.80 | 2023-2025 | Verquvo |
| Medtronic Vascular, INC. | $248.84 | 2019 | |
| Boston Scientific Corporation | $232.44 | 2022-2024 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.51 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $191.93 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $154.26 | 2022-2025 | Wainua, Farxiga, Lokelma |
| Abbott Laboratories | $145.12 | 2019 | |
| Scpharmaceuticals INC. | $124.78 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $97.32 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $81.66 | 2022-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $62.15 | 2023 | Assure Wcd |
| Chiesi USA, INC. | $43.83 | 2023 | Kengreal, Cleviprex |
| Esperion Therapeutics, INC. | $37.14 | 2023-2024 | Nexletol |
| Lantheus Medical Imaging, INC. | $36.44 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $20.37 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.